Like yesterday's post...not exactly news...but, now this:
Repeated
in-field radiosurgery for locally recurrent brain metastases:
Feasibility, results and survival in a heavily treated patient
cohort. Balermpas,
Stera, Muller von der Grun, et al. PLoS One. 2018 Jun 6.
Stereotactic radiosurgery (SRS) is an
established primary treatment for newly diagnosed brain metastases
with high local control rates. However, data about local
re-irradiation in case of local failure after SRS (re-SRS) are rare.
We evaluated the feasibility, efficacy and patient selection
characteristics in treating locally recurrent metastases with a
second course of SRS.
We retrospectively evaluated patients
with brain metastases treated with re-SRS for local tumor progression
between 2011 and 2017. Patient and treatment characteristics as well
as rates of tumor control, survival and toxicity were analyzed.
Overall, 32 locally recurrent brain
metastases in 31 patients were irradiated with re-SRS. Median age at
re-SRS was 64.9 years. The primary histology was breast cancer and
non-small-cellular lung cancer (NSCLC) in respectively 10 cases
(31.3%), in 5 cases malignant melanoma (15.6%). In the first
SRS-course 19 metastases (59.4%) and in the re-SRS-course 29
metastases (90.6%) were treated with CyberKnife® and the others with
Gamma Knife. Median planning target volume (PTV) for re-SRS was 2.5
cm3 (range, 0.1-37.5 cm3) and median dose prescribed to the PTV was
19 Gy (range, 12-28 Gy) in 1-5 fractions to the median 69% isodose
(range, 53-80%). The 1-year overall survival rate was 61.7% and the
1-year local control rate was 79.5%. The overall rate of radiological
radio-necrosis was 16.1% and four patients (12.9%) experienced grade
greater/ = to 3 toxicities.
A second course of SRS for locally
recurrent brain metastases after prior local SRS appears to be
feasible with acceptable toxicity and can be considered as salvage
treatment option for selected patients with high performance status.
Furthermore, this is the first study utilizing robotic radiosurgery
for this indication, as an additional option for frameless
fractionated treatment.So this is a look at only a handful of patients with mixed cancers, but having SRS as a second go round for brain tumors can be helpful with manageable side effects. (Of course, side effects are much more manageable when you are not the rattie!!!)
For what it's worth - c
No comments:
Post a Comment